July 30, 2012

Spectrum Pharmaceuticals Named One of the Best Places to Work in Orange County

  • This is third time Spectrum has been recognized by awards program conducted
    by Orange County Business Journal and Best Companies Group
  • Survey to report company rankings in October based on workplace practices and employees' satisfaction

HENDERSON, Nevada--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it was named one of the Best Places to Work in Orange County by the Orange County Business Journal and Best Companies Group.

The awards program was designed to identify, recognize and honor the best employers in Orange County, benefiting the county's economy, workforce and businesses. Companies from across the county were assessed based on company size (small, medium or large). Spectrum has been named one of this year's Best Places to Work in Orange County in the medium category (50-249 U.S. employees).

The survey process included the evaluation of a company's workplace policies, practices, philosophy, systems and demographics. The second part consisted of an employee survey to measure employees' satisfaction. The combined scores determined the top companies and the final rankings.

Best Companies Group managed the survey process in Orange County, analyzed the data and determined the final rankings. The actual rankings will be published in the Orange County Business Journal's special report on the Best Places to Work in the October 29, 2012 issue of the Orange County Business Journal.

"This is Spectrum's third time being named one of the 'Best Places to Work' and it is a continued source of pride for the Company. Our team has expertise and passion in the business and every employee brings a unique skill and voice that is critical to the success of our Company," stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "With a dedicated and passionate team, we are able to accomplish our goals effectively and in the best interest of cancer patients. It is an honor to work alongside such motivated and committed people for a cause we all deeply believe in, to provide most optimal treatment options for people suffering from cancer."

Spectrum Pharmaceuticals maintains a research and development facility in Irvine, CA, with headquarters in Henderson, Nevada.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum currently markets two oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S. and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Spectrum Pharmaceuticals, Inc.
Shiv Kapoor, 702-835-6300
Vice President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Spectrum Pharmaceuticals, Inc.